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KEPATUHAN KEPADA RAWATAN INSULIN DALAM KALANGAN 
PESAKIT DIABETES MELLITUS JENIS 2 YANG MENERIMA RAWATAN 





Pesakit Diabetes Mellitus Jenis 2 (DMJ2) memerlukan terapi insulin bagi mencapai 
tahap glisemik yang disasarkan dan mencegah komplikasi berkaitan dengan diabetes 
mellitus. Kajian ini bertujuan untuk menentukan kadar pematuhan terhadap terapi 
insulin kepada pesakit yang mendapatkan rawatan di pusat-pusat penjagaan kesihatan 
primer Kementerian Kesihatan dan untuk mengenalpasti faktor-faktor yang berkaitan 
kepada kepatuhan. Kaitan antara tahap kepatuhan dan tahap glisemik (HbA1C, RBS 
dan FBS) juga telah dinilai.  Kajian keratan rentas ini telah dijalankan ke atas pesakit 
DMJ2 yang berumur 18 tahun ke atas yang menggunakan terapi insulin sekurang-
kurangnya dua bulan. Kaedah persampelan tujuan telah digunakan. Kajian ini 
melibatkan 249 subjek dari lima pusat-pusat penjagaan kesihatan primer Kementerian 
Kesihatan di Klang, Selangor. Pesakit telah ditemubual dan data mengenai sosio-
demografi, faktor-faktor yang berkaitan dengan penyakit, faktor-faktor berkaitan 
rawatan dan parameter klinikal telah didokumenkan. Satu soal selidik Kepatuhan 
Terhadap Insulin yang telah disahkan dan dijawab sendiri oleh pesakit telah 
digunakan. Regresi Logistik Binari telah digunakan untuk mengenalpasti faktor-faktor 
yang signifikan berkaitan dengan kepatuhan terhadap terapi insulin.  Peratusan 
kepatuhan kepada terapi insulin hanya 8.43% (95% selang keyakinan (SK): 0.05, 
0.12). Selepas pelarasan semua faktor-faktor yang berkait, tiga faktor didapati 
xii 
 
signifikan. Faktor-faktor yang berkaitan dengan kepatuhan insulin adalah pemantauan 
kendiri glukosa darah yang mempunyai 5.49 kali kebarangkalian kepatuhan kepada 
terapi insulin (Nisbah ods terlaras (NOT)=5.39, 95% SK: 1.20, 24.13). Seorang 
pesakit yang mengamalkan aktiviti senaman mempunyai 3.38 kali kebarangkalian 
kepatuhan kepada terapi insulin (NOT=3.38, 95% SK: 1.37, 10.03). Terdapat 
peningkatan 63% ke atas kebarangkalian kepatuhan kepada terapi insulin pada setiap 
satu unit peningkatan dalam kekerapan dos insulin sehari (NOT=1.63, 95% SK: 1.09, 
2.44). Tiada kaitan antara tahap kepatuhan dan tahap glisemik. Kepatuhan kepada 
terapi insulin adalah rendah. Pesakit yang mengamalkan pemantauan glukosa darah 
kendiri, senaman dan kekerapan dos insulin sehari adalah faktor-faktor yang 
mempengaruhi kepatuhan ke atas terapi insulin. Hasil klinikal pesakit DMJ2 boleh 
dipertingkatkan melalui identifikasi yang lebih baik dan spesifik ke atas faktor-faktor 
yang membawa kepada pematuhan terapi insulin. 
 
Kata Kunci: insulin, pemantauan kendiri glukosa darah, pematuhan, senaman, 
kekerapan dos insulin dalam sehari, kepatuhan insulin, diabetes mellitus  
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ADHERENCE TO INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS 
PATIENTS TREATED AT THE GOVERNMENT’S PRIMARY HEALTH 




Insulin therapy is necessary for Type 2 Diabetes Mellitus (T2DM) patients to 
accomplish targeted glycaemic level and to prevent diabetes-related complications. 
This study aimed to determine the proportion of adherence to insulin therapy in 
patients who attended Ministry of Health’s primary care centers and its associated 
factors. The association between adherence level and glycaemic control was also 
studied. This cross-sectional study was conducted among T2DM patients aged 18 
years and above and who were on insulin therapy for at least two months. A purposive 
sampling method was used. This study involved 249 subjects from five Ministry of 
Health’s primary care centers in Klang. Patients were interviewed, and records were 
accessed to collect data on socio-demographic characteristics, disease-related factors, 
treatment-related factors and clinical parameters. A self-administered validated 
questionnaire was used. Significantly associated factors were identified by using 
Binary Logistic Regression. The proportion of adherence to insulin therapy was only 
8.43% (95% CI: 0.05, 0.12). After adjusting for confounders, three variables were 
found to be significant. Factors associated with insulin adherence were self-
monitoring of blood glucose (SMBG) (Adjusted OR=5.39, 95% CI: 1.20, 24.13), 
exercise (Adjusted OR=3.38, 95% CI: 1.37, 10.03), and number of daily insulin 
injections (Adjusted OR=1.63, 95% CI: 1.09, 2.44). There was no association between 
adherence level and glycaemic parameters. Insulin therapy was poor. Patient who 
xiv 
 
practiced SMBG, exercised and had more frequent daily insulin injections 
significantly affected the adherence to insulin therapy. T2DM patients’ clinical 
outcomes could be improved through a better and specific identification of factors that 
could lead to the adherence to insulin therapy. 
 
Keywords: insulin, self-monitoring of blood glucose, exercise, daily insulin 
injections, insulin adherence, type 2 diabetes mellitus
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         CHAPTER 1 
INTRODUCTION 
1.1. Background of the Study 
 
Type 2 Diabetes Mellitus (T2DM) is demonstrated by elevated blood glucose levels 
and other metabolic imbalances. It is mainly due to inadequate insulin secretion and 
resistance in the body. There is a progressive loss of β-cell function and consequently, 
impairment of insulin secretion and subsequently, defects in insulin action (American 
Diabetes Association, 2015; Ministry of Health Malaysia, 2015a). 
 
T2DM is one of the most common non-communicable diseases globally and 
increasing all over the world year after year (Wallia and Molitch, 2014). In 2011, it 
was estimated that 366 million people worldwide had diabetes mellitus (DM), 
corresponding to a global prevalence of 8.3% (Cani et al., 2015). In 2012, diabetes 
caused 1.5 million deaths worldwide, and the uncontrolled level of blood glucose 
contributed to a further 2.2 million deaths due to increasing risks of cardiovascular 
and other complications (World Health Organization, 2016). A study by Guariguata 
et al. (2014) estimated that in 2035, 592 million of the world population would have 
DM and large proportions of them live in the low and middle-income countries. As 
most countries moving towards an aging nation, the shift of demographic pattern 
would result in increased number of people more than 65 years of age with DM (Wild 
et al., 2004). 
 
In Malaysia, there is a rising trend on the prevalence of T2DM. National Morbidity 
Surveys conducted routinely by the Ministry of Health Malaysia showed increasing 
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trend from 6.3% in 1986 to 8.3% in 1996, 11.6% in 2006, 15.2% in 2011, 17.5% in 
2015 and projected to rise to 20.6% in 2020. The latest survey found out that one in 
five Malaysians was diabetic. Categorically by age group, in 2015, 9.4% of those aged 
30 to 34 had diabetes, almost double from 4.9% in 2006. For 35 to 39 years old, it was 
increased from 6.4% to 10.9% for the same period. For those aged 40 to 44, it rose 
from 10.3% to 17.6%, and those aged 45 to 49 saw a rise from 15% to 20.6% (Ministry 
of Health Malaysia, 2015b). Among patients with known T2DM, 25.1% were on 
insulin therapy (Ministry of Health Malaysia, 2015a). 
 
A key component to ensure the success of a therapeutic regime is to ensure that 
patients adhere to the recommended and tailored medication regime set up by the 
healthcare professionals.  
 
1.2. Justifications of the Study 
 
Patients with chronic diseases require long-term treatments and monitoring. Among 
chronic diseases, diabetes had significant medical, social and economic burdens, as 
well as physical and cognitive impairments (Sabaté, 2003). 
 
Recent studies in Malaysia showed that diabetes control was poor among patients 
attending public hospitals in Malaysia (Mafauzy et al., 2011; Ministry of Health 
Malaysia, 2015a; Mohamed, 2016). The percentage of diabetic patients which were 
under optimum control was only 13% in tertiary centers and 24% for primary care 
centers (Ministry of Health Malaysia, 2015a). 
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Patients with T2DM is manifested by a chronic hyperglycemic state and this is 
primarily due to insulin deficiency and/or resistance (Ministry of Health Malaysia, 
2015a). Furthermore, despite the advancement of treatment and the progression of 
knowledge on T2DM, treatment adherence to pharmacological treatment is still 
unsatisfactory and a serious concern. A study by Purran et al. (2015) showed that the 
proportion of adherence to insulin therapy in a tertiary centre was unsatisfactory 
(19%). This study was conducted among Malay diabetic patients in the East Coast of 
Malaysia. Therefore, adherence rate in other races in Malaysia was still unknown.  
 
Generally, T2DM is an important risk factor for other comorbidities such as 
cardiovascular diseases and long-term complications such as retinopathy, neuropathy, 
nephropathy and cerebrovascular complications Lerman et al. (2009) & Rhee et al. 
(2005). Non-adherence may lead to complications of DM related diseases and a 
financial burden to the patients and the government.  
 
Therefore, it is of prime importance for a further study to measure insulin adherence 
in the primary settings using the same research tool. The chosen area of Klang district 
has multi-racial and well-balanced races between Malay, Chinese and Indian. 
Therefore, this study can generate a more general result on adherence to insulin 
therapy which can be inferred to the multi-racial Malaysian population. 
 
1.3. Research Questions 
1. What was the level of adherence to insulin therapy in T2DM patients treated 
at the government’s primary health care centers? 
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2. What were the factors associated with adherence to insulin therapy in T2DM 
patients who were treated in the government’s primary health care centers? 
3. Was adherence to insulin therapy associated with a well-controlled glycaemic 
levels (HbA1c, RBS, and FBS) in T2DM patients who were treated in the 
government’s primary health care centers? 
 
1.4. General Objectives 
To study the adherence of insulin therapy and its associated factors in T2DM patients 
who were treated in the government’s primary health care centers in Klang, Selangor. 
 
1.5. Specific Objectives 
1. To determine the proportion of adherence to insulin therapy in T2DM patients 
treated at the government’s primary health care centers in Klang by using a 
validated Bahasa Malaysia version of Insulin Adherence Questionnaire for 
Diabetes Mellitus. 
2. To identify the factors associated with adherence to insulin therapy in T2DM 
patients who were treated at the government’s primary health care centers in 
Klang. 
3. To determine the association between adherence to insulin therapy with a well-
controlled glycaemic levels (HbA1c, RBS, and FBS) in T2DM patients who 
were treated at the government’s primary health care centers in Klang. 
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1.6. Hypotheses Statements 
1. There were significant associations between adherence to insulin therapy in 
T2DM patients who were treated at the government’s primary health care 
centers in Klang and patient-related factors, therapy-related factors, condition-
related factors and socio-economic factors. 
2. Adherence to insulin therapy was significantly associated with a well-
controlled glycaemic levels (HbA1c, RBS, and FBS) in T2DM patients who 
were treated at the government’s primary health care centers in Klang. 
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                                                    CHAPTER 2 
LITERATURE REVIEW 
2.1. Overview of T2DM 
 
There are three types of DM. Type 1 DM (T1DM) is an autoimmune condition which 
is caused by the body attacking its pancreas and genetic predisposition. The damaged 
ß-cells in people with T1DM resulted in the inability of the pancreas to produce 
insulin. The other type is gestational DM which is triggered by pregnancy leading to 
insulin resistance. It is often diagnosed in the second or third trimester (American 
Diabetes Association, 2010). 
 
The third type of DM is T2DM which is characterized by insulin resistance with 
progressive loss of ß-cell function and insulin deficiency. T2DM is a chronic disease 
(American Diabetes Association, 2015) and an important risk factor of other 
comorbidities such as cardiovascular diseases and long-term complications such as 
retinopathy, neuropathy, nephropathy and cerebrovascular complications (Lerman, 
2005; Rhee et al., 2005; Boriani, 2016). 
 
2.2. T2DM Complications 
 
Uncontrolled T2DM may lead to a variety of complications, and it greatly affects 
individual’s quality of life. Diabetic kidney disease, diabetic retinopathy, diabetic 
peripheral neuropathy and diabetic autonomic retinopathy are associated with 
microvascular complications of diabetes (World Health Organization, 2016). Twenty 
to forty percent of patients with diabetes develop kidney disease and subsequently 
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end-stage renal disease. A local study performed by Abougalambou and 
Abougalambou (2012) reported that the prevalence of nephropathy secondary to DM 
was 54.3%. 
 
Autonomic neuropathy consists of hypoglycaemia, tachycardia, orthostatic 
hypotension, gastroparesis, constipation, diarrhea, fecal incontinence, erectile 
dysfunction, neurogenic bladder, and sweating (Sarbacker and Urteaga, 2016). In 
addition, the presence of atherosclerotic cardiovascular disease complications is the 
leading cause of morbidity and mortality in individuals with T2DM (American 
Diabetes Association, 2015). Therefore, it is of prime importance for patients with 
T2DM to achieve glycaemic control and lower HbA1c to reduce onset or progression 
of complications (Krass et al., 2015; Sarbacker and Urteaga, 2016).  
 
2.3. Glycaemic Indicator for DM Control 
 
There are three types of glycaemic control to measure the amount of glucose or sugar 
in the body which are fasting blood sugar (FBS), random blood sugar (RBS) and 
HbA1C. A blood glucose test and the glycaemic levels can help to diagnose and 
determine the severity of DM. 
 
In Malaysia, RBS test is an easier method to screen a patient with T2DM (Ministry of 
Health Malaysia, 2015a) as patients are not required to fast before undergoing the 
procedure. However, it is less sensitive compared to FBS and HbA1C (American 
Diabetes Association, 2015). An individual with ≥11.0 mmol/L is considered to have 
T2DM (Ministry of Health Malaysia, 2015a). Based on the clinical practice guideline, 
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there is no statement on the frequency of RBS test needed to be done on T2DM 
patients. However, RBS test is commonly and routinely being practiced in facilities 
under Ministry of Health Malaysia. 
 
The American Diabetes Association (American Diabetes Association, 2015) has 
recommended the use of FBS for the initial screening of DM because it is easier, faster, 
has less intra-individual variation and has high predictive value for the development 
of the microvascular complications of DM. The major disadvantage of FBS test is that 
patients need to fast overnight before undergoing the procedure. An individual with 
≥7.0 mmol/L is considered to have T2DM, and the test should be done annually on all 
T2DM patients (Ministry of Health Malaysia, 2015a).  
 
Unlike FBS which needed the patient to fast before the procedure, the HbA1C test can 
be performed at any time of the day. This advantage has made it the ideal test for 
assessing glycaemic control in people with diabetes (Committee, 2009; World Health 
Organization, 2011). On top of that, HbA1c mimics average plasma glucose over the 
past eight to 12 weeks (Nathan et al., 2007). Therefore, it can avoid the issue of 
inaccurate and variability of glycaemic values (World Health Organization, 2011). 
The recommended cut-off point for HbA1C is set at 6.5%. A value of more than that 
6.5% indicates that the glycaemic levels of the patient are uncontrolled (World Health 
Organization, 2011; Ministry of Health Malaysia, 2015a). 
 
HbA1C was initially recognized as an ‘unusual’ haemoglobin in patients with diabetes 
(Rahbar et al., 1969). From there on, studies were done considering the relationship 
of HbA1C and glucose levels in the body. Based on numerous studies, it is now well 
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established that there is a strong correlation between HbA1C and average glucose 
across a range of diabetes types and patient populations (Nathan et al., 2007). In the 
1980s, HbA1C was introduced and used in clinical settings and later became a gold 
standard for identifying and diagnosing diabetic patients (Massi-Benedetti, 2006).  
 
To prevent long-term complications of patients with T2DM, HbA1c level ought to be 
maintained at 7% or less. In addition, HbA1c goals must be personalized according to 
patient’s age, comorbidities, available resources, and risks of hypoglycaemia (Wallia 
and Molitch, 2014; Ministry of Health Malaysia, 2015a). A retrospective cohort study 
in the United Kingdom in between 1995 to 2005 involving 14 824 T2DM patients 
discovered that majority of patients had poor glycaemic control (Calvert et al., 2007). 
In addition, Holman et al. (2008) also reported that majority of patients did not achieve 
the required level of HbA1c.  
 
A study done by Al Balushi et al. (2014) found out that only 2.4% patients achieve the 
targets of six diabetes-related factor which are HbA1c, blood pressure, total cholesterol, 
high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and 
triglycerides. In addition, HbA1c level in Malaysia was found to be suboptimal where 
ethnicity, insulin, and medications were found to be the predicting factors (Ahmad et 
al., 2011). In addition, a study performed by Cani et al. (2015) showed a decrease in 
HbA1c by 0.57% (P <0.001) in insulin-treated patients with T2DM.  
 
To reduce the long-term complications of T2DM, proper control of glycaemic levels 
is important (American Diabetes Association, 2015). Apart from pharmaceutical 
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intervention, behavioral modifications such as changes in dietary lifestyle and 
education regarding physical activity are also paramount in managing T2DM. 
 
2.4. Treatment Recommendations for T2DM 
2.4.1. Behavioral Modifications 
 
 
The management of T2DM involves multitudes of therapies. The therapies depend on 
the duration and severity of illness and individual’s overall state of health and lifestyle 
(Edelman, 1997). The initial treatments are to initiate changes in lifestyle. In principle, 
all patients with T2DM should undergo lifestyle modification, which consists of 
proper dietary therapy and increased physical activity (Ministry of Health Malaysia, 
2015a). 
 
Proper diet is crucial in the management of T2DM at any stage and including those on 
medication. This proper dietary habit can be achieved through healthy food choices. 
The role of a dietitian is crucial to guide T2DM patients to control their dietary habit 
better and therefore, to control their glycaemic level (Ministry of Health Malaysia, 
2015a).  Lifestyle changes alone including healthy food and regular exercise are 
sufficient for glycaemic control in many patients with newly diagnosed T2DM.  
 
In addition to diet changes, enhancement of physical activity and exercise are also 
essential in DM management. The primary goal is to assist in weight loss and control 
of glycaemic levels in the blood (American Diabetes Association, 2015; Gardner, 
2015). Increased physical activity can improve glycaemic control, assist with weight 
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maintenance, and reduce the risk of complication due to DM (Ministry of Health 
Malaysia, 2015a). 
 
Compared with dietary manipulation alone, intensified therapy in the form of oral 
antidiabetic agents or insulin significantly has more impact towards the management 
of proper glycaemic control and reduced the development of microvascular 
complications (UK Prospective Diabetes Study Group, 1998). In addition, poor 
adherence to lifestyle modifications in Malaysia (Hussein et al., 2015) are common, 
and therefore, the introduction of pharmacological management is needed. 
 
2.4.2. Pharmacological Management 
 
There are broad classes of pharmacologic management in treating T2DM patients. It 
depends on their modes of action, safety profiles, and tolerability and can be classified 
into either oral hypoglycaemic agents (OHA) and/or insulin therapy.  
 
2.4.2 (a) Oral Hypoglycaemic Agents 
 
The OHA include agents that stimulate insulin secretion (sulphonylureas and rapid-
acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion 
and absorption of intestinal carbohydrate (α-glucosidase inhibitors) or improve insulin 
action (thiazolidinediones) (Krentz and Bailey, 2005). 
 
The preferred pharmacological therapy for T2DM is metformin (Krentz and Bailey, 
2005). Other second-line agents include sulfonylureas, meglitinides, 
thiazolidinediones, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, 
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sodium–glucose cotransporter 2-inhibitors, glucagon-like peptide receptor agonists, 
and amylin mimetics (American Diabetes Association, 2015; Ministry of Health 
Malaysia, 2015a; Sarbacker and Urteaga, 2016). The necessary factors in deciding the 
need for oral medications or insulin therapy depending on the clinical condition of the 
patient, state of glycaemic control and presence of any complications (Ministry of 
Health Malaysia, 2015a).  
 
A study done locally by Mohamed (2016) found that the most commonly prescribed 
oral anti-hyperglycaemic agents was metformin (78.6%) and followed by 
sulphonylureas (35.4%).  
 
2.4.2 (b) Insulin Therapy 
 
Over time, insulin secretion capability deteriorates, and most individuals with T2DM 
would eventually require the usage of insulin therapy to maintain their glycaemic 
controls (American Diabetes Association, 2015). It is the most effective therapy for 
better management of glycaemic control (Sarbacker and Urteaga, 2016), especially 
when combination therapy has failed (Korytkowski, 2002). A study by Bennett et al. 
(2011) found out that individual oral hypoglycaemic agents (OHA) usually do not 
decrease the levels of HbA1c by more than 1%. Therefore, insulin therapy is eventually 
necessary to achieve better glycaemic control (Raskin et al., 2005; Garber et al., 2006; 
Inzucchi et al., 2012; Home et al., 2014).  
 
Many evidence suggests that insulin therapy should be initiated earlier in diabetes 
treatment (Garber, 2003). Inability to achieve adequate glycaemic control with a 
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combination of OHAs is likely to indicate that the natural history of DM has 
progressed to a state of severe β-cell failure. At this juncture, it is necessary to switch 
to insulin therapy (Krentz and Bailey, 2005). A delayed introduction or ineffective 
insulin therapy would contribute to poor glycaemic control and increase the likelihood 
of patients to develop complications (Cahn et al., 2015). 
 
The type of insulin introduced need to be individualized, based on the pathophysiology 
of T2DM, the clinical condition of the patient, dietary pattern and lifestyle 
modification (Wallia and Molitch, 2014; Ministry of Health Malaysia, 2015a).  
 
There is a wide range of treatment options and regiments of insulin which can be 
initiated in patients with T2DM. Currently, there are two types of insulin which are 
commonly prescribed to T2DM patients in Malaysia. These are human insulin derived 
recombinant technology and insulin analog (genetically modified human insulin). 
Both types of insulin are further divided into prandial, basal and premixed as per their 
pharmacokinetic profiles. 
 
Prandial insulin is administered before-meal because of its short or rapid onset of 
activity in controlling postprandial glucose. Basal insulin is given to a patient requiring 
insulin therapy once or twice daily. The intermediate or long-acting pharmacokinetic 
profile covers the basal insulin requirements in between meals and night time. 
Premixed insulin combines both the short or rapid-acting insulin with intermediate-
acting insulin into one formulation to cover for both postprandial glucose excursion 
as well as basal insulin needs (Ministry of Health Malaysia, 2015a). 
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Basal insulin can be added to OHAs initially while prandial insulin can be added later 
using one of the multiple strategies in a stepwise fashion based on the clinical 
condition of the patient (Home et al., 2014; Wallia and Molitch, 2014). A survey on 
utilization of medications in diabetic patients was conducted in the United States of 
America in 2012. The study discovered that only 2.9 million people (14%) used insulin 
only and 3.1 million (14.7%) used a combination of insulin and oral medications. 
Furthermore, 11.9 million (56.9%) used only oral medications only, and 3 million 
(14.4%) did not use any medicines (Sarbacker and Urteaga, 2016). 
 
The Diabetes, Wishes and Needs (DAWN) study concluded that initially, both health-
care professionals and patients might have a negative attitude towards starting insulin 
therapy (Alberti, 2002) and therefore leading to the barriers towards adherence of 
patients to insulin therapy. 
 
2.5. Medication Adherence and Its Importance in T2DM 
 
The terminologies ‘adherence’ and ‘compliance’ have been used interchangeably to 
define the way patients take their prescribed medications. Previously, the term 
‘compliance’ was widely used in which patients were blindly and passively following 
the instruction of medicines consumption. Nowdays, the term ‘adherence’ was more 
widely accepted in the medical field as it describes what is the extent patients were 
taking their medication, their involvement in the medication decision prescribed and 
overall lifestyle changes to improve their clinical symptoms (Ahmed and Aslani, 
2014). In addition, World Health Organization (WHO) states adherence as “the extent 
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to which the persons’ behavior (including medication-taking) corresponds with agreed 
recommendations from a healthcare provider.” (Sabaté, 2003). 
 
Adherence to medication is complex and involves multi-factorial scope that can 
influence patient’s behavior and treatment effects (Gardner, 2015). Non-adherence 
leads to poor clinical outcomes, increase in morbidity, higher death rates, and 
unnecessary healthcare expenditure (Johnson et al., 1999; Brown and Bussell, 2011; 
Mafauzy et al., 2011).  
 
The effectiveness of treatment is mainly dependent on the level of adherence towards 
the prescribed medication (Paes et al., 1998; Ahmad et al., 2013) and accurate 
reporting of adherence problems (Vitolins et al., 2000). Multiple factors leading to 
poor adherence are socioeconomic factors, therapy-related factors, patients-related 
factors, condition-related factors and health system-related factors (Sabaté, 2003). The 
conceptual framework of the study which consists of factors leading adherence to 
insulin therapy is shown in Figure 2.1. 
 
Studies by Mann et al. (2009) and Aikens and Piette (2013) in the United States of 
America showed that the adherence to hypoglycaemic agents including insulin therapy 
was 28%. A study done by AlHewiti (2014) reported that 56.9% had low-adherence 
and it is associated with negative views to medications. Recently, a study was done by 
Yavuz et al. (2015) in Turkey found out that the adherence was 78%.   
 
A systematic review was done by Cramer (2004) from previous studies deduced that 
the adherence to oral anti-diabetic agents drugs ranged from 36% to 93% and 
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specifically between 62-64% adherence rates for insulin therapy. These findings were 
consistent with a study done by Ahmad et al. (2013) in Malaysia which stated that 
53% T2DM patients did not adhere to hypoglycaemic agents including insulin therapy. 
However, a study done by Mashitani et al. (2013) found out that the adherence rate in 
the Japanese population to be as high as 70.65%. The rate of adherence, or the 
variables affecting adherence may vary according to nationality, tools used to measure 
adherence, culture or subculture (Sabaté, 2003). 
 
A study by Purran et al. (2015) of 156 patients showed that the proportion of adherence 
to insulin therapy in a tertiary hospital in Kelantan was only 19% and 98% of patients 
did not achieve the desired level of HbA1c of less than 6.5%. Reasons for non-
adherence are multifactorial. Studies done in different settings with various type of 
sample population regarding races, culture, lifestyle, education and income might 
yield different findings. 
 
Rubin et al. (2009) identified several characteristics of diabetic management that may 
lead to non-adherence of therapy. Firstly, is the individual’s perspective of the effects 
of diabetes of his or her personal lifestyle and secondly is the complexity of the regime. 
Edelman and Pettus (2014) commented that “once insulin therapy is initiated, 
adherence to treatment often is poor with many patients omitting or altering their 
insulin doses.” Furthermore, the authors also deduced that the risks of future 
complication and financial burden would be increased if the patients were non-
adherent to insulin therapy. The involvement of both patient and health care provider 
is essential in the accomplishments of adherence of medications to T2DM and 
therefore, effective insulin therapy (Peyrot and Rubin, 2011). 
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Adherence to insulin therapy is crucial in the management of diabetes. The adherence 
and control of insulin therapy would result in the improved levels of postprandial 
blood glucose, fasting blood glucose and HbA1c and thus, reduce the risk of developing 
complications secondary to T2DM (Doggrell and Warot, 2014). However, only a 
small number of patients in the primary settings achieved the desired level blood 
glucose and diabetes control (Spann et al., 2006). 
 
A study conducted by Garcia-Perez et al. (2013) discovered that variety of factors 
might influence adherence to medication for DM patients. Factors associated with 
reduced adherence are the complexity of medication regimens, adverse events, the 
perception of efficacy and safety, financial considerations and patient-healthcare 
provider relationship. On the other hand, factors associated with improved adherence 
are reduced treatment complexity, education and increased knowledge, ensure benefits 
outweigh costs and improved continuity of care. 
 
Enhancing the effectiveness of adherence towards medication regime may contribute 
a significant impact on the health of the population than any other improvement in 
specific medical treatment (Haynes et al., 2008). Furthermore, adherence to 
pharmacotherapy intervention is crucial in glycaemia controls, reduce long-term 
complications and improve patient’s health outcomes (American Diabetes 





2.6. Assessment Tools Used in Measuring Adherence 
 
An important component to measure the adherence of a patient towards medication is 
identifying its occurrence. The extent of treatment’s adherence can be directly or 
indirectly measured. Direct measurements can be monitored by directly observing the 
treatment received, therapeutic drug monitoring and biomarkers (Vermeire et al., 
2001). However, most often, health care providers do not have access or limited 
opportunities to assess medication adherence by using direct measurement. Therefore, 
indirect measurements by way of record review, clinical assessment, pill count and 
questionnaire (Vermeire et al., 2001; Horne et al., 2005) may assist health care 
providers to assess medication adherence of a patient. 
 
According to Sabaté (2003), studies conducted from 1980 to 2001 in measuring the 
adherence to DM regime yielded inconsistent findings. These inconsistent results 
might be due to several factors which were due to variability in research design, 
sampling frame employed, the use of general measures, sample sizes and lack of 
control of potentially confounding variables. The complexity of regime in managing 
T2DM has been recognized as a challenge to adherence to therapy. 
 
A systematic review that was done by Stolpe et al. (2016) reported that there were 
numerous approaches to measuring adherence to insulin, namely using a self-
administered questionnaire or filling of medicines. Reported methods which were 
commonly used in research studies were medication possession ratio, the proportion 
of days covered, persistence, daily average medication consumption, and the Morisky 
Adherence Scale. However, all methods were associated with a variety of challenges 
concerning the accuracy of estimated adherence, the complexity of data collection, the 
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absence of validated cut-off points for good adherence and reliability of adherence 
outcomes. This is due to the complexity of the measuring adherence level for 
injectable therapies as compared to oral medications. 
 
Every adherence measurement tools have its strength and weaknesses (Williams et al., 
2013). A high number of patients with diabetes use insulin injection as one of their 
medication. Presently, there is no gold standard available for measuring medication 
adherence. Interestingly, questionnaires have been found to provide a more accurate 
assessment of adherence in comparison with other methods such as pill counts or 
biological assays (Arroyo et al., 2011). 
 
Previous studies measuring adherence level to insulin used a general version of 
questionnaires (Cramer, 2004; Peyrot et al., 2010; Peyrot et al., 2012) and did not 
specifically measure all the factors related to insulin therapy. Purran et al. (2015) had 
developed and validated an Insulin Adherence Questionnaire for Diabetes Mellitus 
(IAQDM) with good internal consistency and reliability specifically to measure the 
adherence to insulin therapy. The IAQDM consist of 34 items measuring the factors 
that leading to the adherence to insulin therapy. 
 
2.7. Associated Factors of Adherence to Medication 
 
The proportion of non-adherence to insulin therapy appear to be influenced by a 
variety of factors. Although plenty of studies were done to detect the factors associated 
with adherence to insulin, there was still inconsistency among studies (Rubin et al., 
2009; Peyrot et al., 2012).  
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2.7.1. Socio-demographic Factors 
 
In accordance with previous studies, there was a clear indication that the older the age, 
the higher the adherence to medication (Ahmad et al., 2013; Curkendall et al., 2013; 
Tunceli et al., 2015; Yavuz et al., 2015). Adherence was higher among patients aged 
65 through 79 (Adjusted OR=1.36, 95% CI: 1.21, 1.52) and aged 80 years and older 
(Adjusted OR=1.41, 95% CI: 1.25, 1.59), compared to those aged 55 through 64 
(Curkendall et al., 2013). A study done by Tunceli et al. (2015) found out that patients 
aged less than 45 years old were 65% less likely to adhere to medications than older 
patients aged 45 to 65 years old (Adjusted OR=0.35, 95% CI: 0.33, 0.36). In Malaysia, 
Ahmad et al. (2013) found out similar outcome where younger age was 3% less likely 
to adhere compared to older age (Adjusted OR=0.97, 95% CI: 0.95, 0.99). It is possible 
that younger patients were less aware of their disease and thus more likely to be more 
non-adherent. 
 
Male were more adherent to antihyperglycemic agents compared to female (Adjusted 
OR=1.14, 95% CI: 1.11, 1.17) (Tunceli et al., 2015). However, a study done locally 
found out that females were more adherent to antihyperglycemic agents compared to 
male (Adjusted OR=2.33, 95% CI: 1.10, 4.93) (Ahmad et al., 2013). The contradictory 
findings might be the result of different culture and belief among the sample 
population.  
 
A study by Napolitano et al. (2016) in Italy found out that patients with a college 
degree or tertiary level of education were more likely to adhere to pharmacotherapy 
compared to those with a lower education level among patients with chronic 
conditions (Adjusted OR=2.05; 95% CI: 1.37, 3.06). Those with secondary school 
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(Adjusted OR=1.68; 95% CI: 1.08, 2.61) and with at least a college degree level of 
education (Adjusted OR=2.42; 95% CI: 1.53, 3.81) were more likely to adhere to 
medicines than those with a primary school or lower level. This study was similar to 
a study by Koprulu et al. (2014) which found that secondary and tertiary educated 
patients were 83% less likely to adhere to medications compared to those with none 
and primary level of education (Adjusted OR=0.17, 95% CI: 0.09, 0.31). A study done 
locally found out that patients with a secondary level of education were 2.72 times 
more adhere to medications compared to those in primary school and no formal 
education (Adjusted OR=2.72, 95% CI: 1.13, 6.55) (Bakar et al., 2016). Findings were 
conclusive where people who were more educated was more likely to remember to 
take their medications. 
 
2.7.2. Disease-Related Factors 
 
The presence of DM comorbidities such as hypertension, dyslipidemia or both 
(Adjusted OR=1.78, 95% CI: 1.06, 2.98) resulted in higher non-adherence rate 
(Ahmad et al., 2013). This was similar to a study by Koprulu et al. (2014), where 
patients with co-morbidities have 76% lower odds to adhere to medications (Adjusted 
OR=0.24, 95% CI: 0.11, 0.51). T2DM patients with comorbidities have more drugs of 
different pharmacological classes. This complex treatment regimen could be a factor 
that contributes towards non-adherence. 
 
Furthermore, duration of illness also plays a contributing factor in non-adherence to 
insulin therapy as studied by Feldman et al. (2014) and Yavuz et al. (2015). These 
findings deduced that longer duration of illness leads to better adherence to therapy. 
Patients with a shorter duration of diabetes of 4.8 years (SD 4.3) were having 
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significantly lower adherence to insulin therapy than the longer duration of diabetes 
of 8.8 years (SD 6.3) (Yavuz et al., 2015). In addition, a study by Feldman et al. (2014) 
found that long (more than 60 months) (Adjusted OR=2.48, 95% CI: 2.38, 2.59) and 
intermediate disease (36-59 months) duration (Adjusted OR=1.46, 95% CI: 1.39, 1.54) 
of illness were associated with higher adherence compared to those with short disease 
duration (1-35 months). Of those diabetes patients with longer duration of illness, 
many are taking multiple diabetes medications that are being actively managed by the 
patients or by their physician. 
 
2.7.3. Treatment-Related Factors 
 
There was an increased likelihood of non-adherence for patients who were on fewer 
than three concomitant medications compared to patients with no other concomitant 
medications (Adjusted OR=0.87; 95% CI: 0.84, 0.89) (Tunceli et al., 2015). Patients 
who took a lower number of total pills per day (Adjusted OR=1.75; 95% CI: 0.66, 
0.87) had 75% higher odds to adhere to medicines than patients who took more 
medicines per day (Napolitano et al., 2016). Furthermore, patients were found to be 
75.6% less likely to adhere to their medications with each unit increase in the number 
of prescribed medications (Adjusted OR=0.24, 95% CI: 0.08, 0.63) (Jarab et al., 
2014). Those studies were consistent with a study by Tunceli et al. (2015) who found 
out that patients on a twice-daily dose were 17% less likely to adhere to medications 
compared to patients with a once-daily dose (Adjusted OR=0.82; 95% CI: 0.80, 0.84). 
Donnelly et al. (2007) also reported that patients with poor adherence were 
significantly prescribed higher doses (66.4 IU/day) compared to those with better 
adherence (40.8 IU/day). These findings were conclusive where patients with higher 
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number of concomitant medications were having poorer adherence to medications. 
Patients with higher number of concomitant medications might a difficulty to adhere 
to the complex pharmacotherapy regime compared to patients with lower number of 
concomitant medications. 
 
Patients had 64% lesser odds (Adjusted OR=0.36, 95% CI: 0.24, 0.87) to adhere to 
their medications if they reported adverse effects on the use of antihyperglycaemic 
agents compared to those who did not experience any adverse effects (Jarab et al., 
2014). Adverse effects which are typically happened in patients receiving insulin 
therapy are weight gain and hypoglycaemia (Russell and Khan, 2007; Wallia and 
Molitch, 2014). 
 
Patients who had used insulin therapy for a shorter duration with a mean (SD) of 5.2 
months (2.4) were more likely to non-adherent to insulin therapy than those on longer 
duration with a mean (SD) of 10.7 months (2.4) (Yavuz et al., 2015). In addition, 
patients with a last visit to the clinic of more than one month has 14 times more likely 
to be non-adherent to medications compared to patients with a last visit of less than 




























Figure 2.1: Conceptual Framework of the Study  
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